open access

Vol 86, No 5 (2015)
ARTICLES
Get Citation

Innovative therapy of ovarian cancer based on overexpression of CD44 receptor

Barbara Bukowska, Agnieszka Marczak
DOI: 10.17772/gp/2428
·
Ginekol Pol 2015;86(5).

open access

Vol 86, No 5 (2015)
ARTICLES

Abstract

Ovarian carcinoma constitutes the main cause of cancer-related death among women. The curability rates remain low despite rapid advances in medicine. Thus, the search for new and improved methods continues, with CD44- targeting as one of them. CD44 is a cell-surface glycoprotein, which binds to its ligand – hyaluronic acid (HA) – and regulates crucial processes such as cell differentiation, proliferation and migration. Overexpression of CD44, observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel, doxorubicin, camptothecin or cisplatin) to cancer cells. In this article, we summarized the current state of knowledge regarding CD44-targeting as a new and more efficient way of ovarian cancer treatment, with high potential and promising therapeutic perspectives.

Abstract

Ovarian carcinoma constitutes the main cause of cancer-related death among women. The curability rates remain low despite rapid advances in medicine. Thus, the search for new and improved methods continues, with CD44- targeting as one of them. CD44 is a cell-surface glycoprotein, which binds to its ligand – hyaluronic acid (HA) – and regulates crucial processes such as cell differentiation, proliferation and migration. Overexpression of CD44, observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel, doxorubicin, camptothecin or cisplatin) to cancer cells. In this article, we summarized the current state of knowledge regarding CD44-targeting as a new and more efficient way of ovarian cancer treatment, with high potential and promising therapeutic perspectives.
Get Citation

Keywords

targeted therapy / ovarian cancer / CD44 /

About this article
Title

Innovative therapy of ovarian cancer based on overexpression of CD44 receptor

Journal

Ginekologia Polska

Issue

Vol 86, No 5 (2015)

DOI

10.17772/gp/2428

Bibliographic record

Ginekol Pol 2015;86(5).

Keywords

targeted therapy / ovarian cancer / CD44 /

Authors

Barbara Bukowska
Agnieszka Marczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl